State of Alaska Department of Revenue Decreases Stock Position in Pfizer Inc. $PFE

State of Alaska Department of Revenue cut its stake in Pfizer Inc. (NYSE:PFE) by 5.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 730,857 shares of the biopharmaceutical company’s stock after selling 40,426 shares during the quarter. State of Alaska Department of Revenue’s holdings in Pfizer were worth $18,621,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of PFE. Fiduciary Alliance LLC boosted its position in Pfizer by 46.4% during the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after purchasing an additional 46,043 shares in the last quarter. Vista Investment Partners LLC increased its position in shares of Pfizer by 236.1% in the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after buying an additional 48,900 shares in the last quarter. Generali Investments CEE investicni spolecnost a.s. raised its stake in shares of Pfizer by 76.4% during the 3rd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock worth $2,784,000 after buying an additional 47,319 shares during the period. Bourne Lent Asset Management Inc. lifted its position in shares of Pfizer by 90.8% during the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after buying an additional 18,200 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH grew its stake in Pfizer by 11.2% in the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,892,663 shares of the biopharmaceutical company’s stock valued at $48,225,000 after acquiring an additional 190,946 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on PFE shares. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Sanford C. Bernstein restated a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research report on Friday, October 31st. Citigroup initiated coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target on the stock. Wolfe Research set a $24.00 target price on Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Finally, Morgan Stanley lowered their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Pfizer has an average rating of “Hold” and a consensus price target of $27.88.

Pfizer Stock Up 0.0%

Shares of NYSE:PFE opened at $25.29 on Friday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69. The stock has a market cap of $143.76 billion, a P/E ratio of 14.70 and a beta of 0.47. The business has a fifty day moving average of $25.25 and a two-hundred day moving average of $24.94. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.